...
首页> 外文期刊>Indian journal of pharmaceutical sciences. >Mechanism(s) involved in carbon monoxide-releasing molecule-2-mediated cardioprotection during ischaemia-reperfusion injury in isolated rat heart
【24h】

Mechanism(s) involved in carbon monoxide-releasing molecule-2-mediated cardioprotection during ischaemia-reperfusion injury in isolated rat heart

机译:一氧化碳释放分子2介导的离体大鼠心脏缺血再灌注损伤中的心脏保护作用的机制

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of the present study was to determine the mechanism(s) involved in carbon monoxide-releasing molecule-2, carbon monoxide-releasing molecule-2-induced cardioprotection. We used the transition metal carbonyl compound carbon monoxide-releasing molecule-2 that can act as carbon monoxide donor in cardiac ischaemia-reperfusion injury model using isolated rat heart preparation. Langendorff??s perfused rat hearts when treated with carbon monoxide-releasing molecule-2 (50 ??M) for 10 min before global ischaemia exhibited significant reduction in postischaemic levels of myocardial injury markers, creatine kinase and lactate dehydrogenase in coronary effluent. Similarly, pretreatment with carbon monoxide-releasing molecule-2 showed significantly improved postischaemic recovery of heart rate, coronary flow rate, cardiodynamic parameters and reduced infarct size as compared to vehicle control hearts. Perfusion with p38 mitogen-activated protein kinase inhibitor, SB203580, a specific inhibitor of ?? and ?? isoform, before and concomitantly with carbon monoxide-releasing molecule-2 treatment abolished carbon monoxide-releasing molecule-2-induced cardioprotection. However, p38 mitogen-activated protein kinase alpha inhibitor, SCIO-469, was unable to inhibit the cardioprotective effect of carbon monoxide-releasing molecule-2. Furthermore, protective effect of carbon monoxide-releasing molecule-2 was significantly inhibited by the protein kinase C inhibitor, chelerythrine, when added before and concomitantly with carbon monoxide-releasing molecule-2. It was also observed that, perfusion with phosphatidylinositol 3-kinase inhibitor, wortmannin, before and concomitantly with carbon monoxide-releasing molecule-2 was not able to inhibit carbon monoxide-releasing molecule-2-induced cardioprotection. Interestingly, we observed that wortmannin perfusion before ischaemia and continued till reperfusion significantly inhibited carbon monoxide-releasing molecule-2-mediated cardioprotection. Our findings suggest that the carbon monoxide-releasing molecule-2 treatment may activate the p38 mitogen-activated protein kinase ?? and protein kinase C pathways before ischaemia and phosphatidylinositol 3-kinase pathway during reperfusion which may be responsible for the carbon monoxide-releasing molecule-2-mediated cardioprotective effect.
机译:本研究的目的是确定一氧化碳释放分子2,一氧化碳释放分子2诱导的心脏保护所涉及的机制。我们使用的过渡金属羰基化合物一氧化碳释放分子2可以在使用离体大鼠心脏制剂的心脏缺血再灌注损伤模型中充当一氧化碳供体。在全球缺血之前,用一氧化碳释放分子2(50 ?? M)处理10分钟,Langendorff的灌流大鼠心脏显示出缺血后心肌损伤标记物,肌酸激酶和乳酸脱氢酶的水平显着降低。类似地,与媒介物对照心脏相比,用一氧化碳释放分子2进行的预处理显示出缺血后心率,冠状动脉流速,心脏动力学参数的改善和梗死面积的减少。用p38丝裂原激活的蛋白激酶抑制剂SB203580(一种特异性的??抑制剂)灌注和??异构体,在释放一氧化碳的分子2处理之前和同时废除了一氧化碳释放的分子2诱导的心脏保护作用。但是,p38丝裂原活化的蛋白激酶α抑制剂SCIO-469无法抑制一氧化碳释放分子2的心脏保护作用。此外,当在释放一氧化碳的分子-2之前或与其同时添加时,蛋白激酶C抑制剂白屈菜红碱显着抑制释放一氧化碳的分子2的保护作用。还观察到,在释放一氧化碳的分子2之前和同时灌注磷脂酰肌醇3-激酶抑制剂渥曼青霉素不能抑制释放一氧化碳的分子2诱导的心脏保护。有趣的是,我们观察到渥曼青霉素在缺血前灌注并持续至再灌注显着抑制一氧化碳释放分子2介导的心脏保护作用。我们的发现表明一氧化碳释放分子2的治疗可能会激活p38丝裂原活化的蛋白激酶?缺血前的蛋白激酶C途径和再灌注过程中的磷脂酰肌醇3-激酶途径,可能与一氧化碳释放分子2介导的心脏保护作用有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号